Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 122 results for bipolar

  1. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

  2. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer in adults. This involves using heat energy both to clear blockage in the bile ducts before inserting stents and to clear blocked stents.

  3. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)

    Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.

  4. Smoking: smoking status for people with long-term conditions (IND97)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38

  5. Antenatal and postnatal mental health (QS115)

    This quality standard covers recognising, assessing and treating mental health problems in women planning, during or after pregnancy (up to a year after childbirth). It also covers the organisation of mental health services for women during and after pregnancy. It describes high-quality care in priority areas for improvement.

  6. Alcohol use: brief intervention for people with SMI (IND200)

    This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 12 months who have received a brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM179

  7. Bipolar disorder: assessment and management (extraordinary review)

    In development [GID-NG10380] Expected publication date: TBC

  8. Rehabilitation for adults with complex psychosis (NG181)

    This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.

  9. How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?

    Recommendation ID CG192/2 Question How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period? Any...

  10. Smoking: support and treatment for people with long-term conditions or SMI (IND98)

    This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM39

  11. Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction

    Awaiting development [GID-IPG10353] Expected publication date: 14 November 2024

  12. Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings (CG120)

    This guideline covers assessing and managing people aged 14 years and over with coexisting severe mental illness (psychosis) and substance misuse. It aims to help healthcare professionals guide people with psychosis with coexisting substance misuse to stabilise, reduce or stop their substance misuse, to improve treatment adherence and outcomes, and to enhance their lives.

  13. Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

    Awaiting development [GID-TA10718] Expected publication date: TBC

  14. Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee (IPG493)

    Evidence-based recommendations on arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. This involves using a radiofrequency probe to heat and smooth any defects and rough edges in the cartilage.

  15. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .